Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

MDX060-05E: An open-label, phase II, extension study of MDX-060 [iratumumab] with gemcitabine in patients with relapsed or refractory Hodgkin's disease previously treated in protocol MDX060-05

Next Previous
X
Search
Trial Profile

MDX060-05E: An open-label, phase II, extension study of MDX-060 [iratumumab] with gemcitabine in patients with relapsed or refractory Hodgkin's disease previously treated in protocol MDX060-05

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 25 Nov 2009

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Iratumumab (Primary) ; Gemcitabine
  • Indications Hodgkin's disease
  • Focus Therapeutic Use

    • Most Recent Events

    • 23 Nov 2009 Actual initiation date (1 Mar 2007) and primary outcome added as reported by M.D. Anderson Cancer Center record.
    • 23 Nov 2009 Status changed from not stated to active, no longer recruiting as reported by M.D. Anderson Cancer Center record.
    • 23 Nov 2009 New source identified and integrated (M.D. Anderson Cancer Center, 2006-0122).

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top